Key Details
Price
$23.70Last Dividend
$0.20Annual ROE
8.40%Beta
1.06Events Calendar
Next earnings date:
Feb 07, 2025Recent quarterly earnings:
Nov 06, 2024Recent annual earnings:
Aug 07, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
Nov 12, 2024Next split:
N/ARecent split:
Dec 19, 2007Analyst ratings
Recent major analysts updates
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
KMT is set to benefit from strong momentum in the Infrastructure segment. The company's measures to reward its shareholders are also encouraging.
Marks fourth consecutive year Kennametal has been included on the list PITTSBURGH , Dec. 9, 2024 /PRNewswire/ -- Kennametal Inc. (NYSE: KMT) announced today that it has been once again named one of America's Most Responsible Companies 2025 by Newsweek. This prestigious award reflects Kennametal's commitment to responsible practices across all aspects of its business, including the environment and social stewardship.
KMT is set to benefit from strong momentum in the Infrastructure segment. However, increasing costs and expenses remain a concern.
– Approval based on positive data from the AUGMENT-101 clinical trial, in which Revuforj delivered robust and durable rates of remission in R/R acute leukemia patients with a KMT2A translocation – – Syndax to host conference call today at 6:00 p.m. ET – WALTHAM, Mass.
PITTSBURGH , Nov. 13, 2024 /PRNewswire/ -- Kennametal Inc. (NYSE: KMT) is proud to announce that it has been recognized as one of Caterpillar Inc's top indirect suppliers in 2024. This prestigious recognition reflects Kennametal's continued dedication to delivering innovative solutions, productivity improvements and outstanding customer and applications engineering support.
Primary endpoint of pivotal phase 2 study met with statistical significance in using Revumenib for the treatment of relapsed/refractory mNPM1 AML patients; sNDA expected 1st half 2025. PDUFA action date of December 26th of 2024 deployed for FDA to decide if Revumenib should be approved for the treatment of relapsed/refractory KMT2Ar Acute leukemia patients. The global acute myeloid leukemia market is expected to reach $5.86 billion by 2030; About 10% of patients have KMT2Ar AML and then 30% have mNPM1 AML.
PITTSBURGH , Nov. 12, 2024 /PRNewswire/ -- Kennametal Inc. (NYSE: KMT) announced today that they will attend the UBS Global Industrials and Transportation Conference in Manalapan, Florida. Details of the conference are as follows: When: Tuesday, December 3, 2024 Attendees: Patrick Watson, Vice President and Chief Financial Officer Michael Pici, Vice President, Investor Relations About Kennametal With over 85 years as an industrial technology leader, Kennametal Inc. delivers productivity to customers through materials science, tooling and wear-resistant solutions.
KMT's fiscal first-quarter 2025 revenues decrease 2% due to the lackluster performance of the Metal Cutting segment.
The headline numbers for Kennametal (KMT) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Kennametal (KMT) came out with quarterly earnings of $0.29 per share, beating the Zacks Consensus Estimate of $0.25 per share. This compares to earnings of $0.41 per share a year ago.
FAQ
- What is the primary business of Kennametal?
- What is the ticker symbol for Kennametal?
- Does Kennametal pay dividends?
- What sector is Kennametal in?
- What industry is Kennametal in?
- What country is Kennametal based in?
- When did Kennametal go public?
- Is Kennametal in the S&P 500?
- Is Kennametal in the NASDAQ 100?
- Is Kennametal in the Dow Jones?
- When was Kennametal's last earnings report?
- When does Kennametal report earnings?
- Should I buy Kennametal stock now?